drugset / Trial / NCT02287025
A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
RandomizedParallel-groupOpen-labelSupportive care
Summary
Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated with regorafenib. Intensified education and support will be provided through an application for iPad which has automatic links to grading, dose reduction and side effect management ,as well as, references for additional articles.
Timeline
- Start
- 2014-11-11
- Primary completion
- 2016-02-26
- Completion
- 2016-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Regorafenib | Small molecule | 160 mg | — |
Indications
No indication recorded.